Background: Pertussis is a highly contagious, vaccine-preventable respiratory infection that is endemic worldwide. There are limited data regarding the occurrence of pertussis in travelers. The objective of this study is to identify travel-related pertussis cases reported to the GeoSentinel Surveillance Network. Methods: This is a descriptive, retrospective analysis of GeoSentinel records from 25 travel/tropical medicine clinics in 16 countries. Frequencies of demographic and travel-related characteristics and symptoms of 74 cases of pertussis in travelers and new immigrants from 1999 to 2015 were analysed. Results: There were 74 probable and confirmed cases of pertussis in the GeoSentinel database; median age was 44 years, and 38 (51%) patients were female. Tourism was the most common reason for travel (41; 55%). Country of exposure was determined in 66 cases with travelers returning from India and China constituting the highest number of cases (10 cases each; 15% each). Seventy of 74 (95%) patients had respiratory symptoms, while fatigue and fever were reported by 21 (28%) and 20 (27%), respectively. Immunization status against pertussis was unknown. Most cases were reported after 2005 (69; 93%). Conclusions: Our study describes 74 cases of pertussis acquired during travel and reported to the GeoSentinel Network. Pertussis should be considered in returned travelers who present with respiratory symptoms. Surveillance and detection of imported cases are important to prevent onward transmission in the community. The pre-travel consultation provides an opportunity to verify immunization status and provide routine vaccinations such as pertussis.
Introduction
Pertussis is a highly contagious respiratory infection of global importance. It is preventable by a vaccine which is on the World Health Organization's List of Essential Medicines. There are two main types of pertussis vaccines: the older whole cell vaccine and the acellular vaccine which has replaced the more poorly tolerated whole cell vaccine in developed countries. In children beyond infancy, the infection usually manifests as a classic whooping cough, but in adults, it more commonly presents as a non-specific chronic cough. 1 Worldwide incidence decreased significantly with the introduction of vaccine in the 1940s to 1960s. Over the past 15 years, however, there has been a gradual increase in the number of cases, even in countries with high rates of immunization. 2 The reasons for this resurgence are multi-factorial and vary by country. Improved diagnosis, shorter duration of vaccine-induced protection and probable decreased efficacy of acellular compared with whole cell vaccines are likely to play critical roles. 3 Vaccine escape Bordetella pertussis strains are emerging. 4 Protection against pertussis is important for travelers who may be exposed during trips to regions of greater pertussis risk. Previous studies have examined the role of respiratory tract infections in travelers, but there are limited data regarding the occurrence of pertussis in particular. Respiratory tract infections were found in 1719/21,960 (7.8%) of returning travelers seen at GeoSentinel sites between 1997 and August 2001 5 ; older age and male sex were associated with increased risk of lower respiratory tract infections. In that analysis, influenza accounted for 96/1719 (5.6%) of cases. A serologic analysis of influenza in travelers found that 86/1190 (7%) of travelers had confirmed influenza infections. 6 Other analyses of respiratory tract infections in travelers have found respiratory tract symptoms in 26% of persons during travel, 10% after travel, 7 and 21% of those requiring medical care during travel 8 ; the proportion of travelers with respiratory symptoms increases with underlying comorbidities (particularly HIV and diabetes mellitus) and age >60 years 9 . As for pertussis, Wilder-Smith et al. 10 observed an incidence of 1.4% among 358 Hajj pilgrims. A recent case series described four returning travelers seen at a Spanish clinic over a period of 3 months. 11 Because of the recent changes in pertussis vaccine formulation and the global resurgence of disease, this study sought to document pertussis infections among international travelers reported to the GeoSentinel Surveillance Network.
Methods
GeoSentinel is a global surveillance network of 63 travel and tropical medicine clinics in 25 countries on 6 continents that systematically collects clinical information on ill travelers. To be eligible for inclusion in the GeoSentinel database, patients must have crossed an international border, sought care at a GeoSentinel site, and have a presumed travel-associated condition. Anonymous surveillance data are collected by sites and entered into a structured query language database. These data include information on demographics, pre-travel consultation, travel type and duration, and area of exposure. Final diagnoses are assigned codes from a standardized list of >500 diagnoses.
12,13
We reviewed data entered into the GeoSentinel database between January 1999 and July 2015. All patients with a diagnosis of probable or confirmed pertussis were included in the analysis. This assessment was made by the clinician at each site, using available diagnostic methods. Information on diagnostic methods used was available from 15 out of 25 sites that contributed cases. The sites entered the country of exposure in most cases; when missing, we assigned it based on travel destinations, symptom onset, and incubation period (range of 4-21 days). Pretravel immunization data are not collected routinely.
Statistical analyses were performed with R 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables are presented as absolute number and percentage. Numeric variables are summarized by median and 25th-75th percentile. Mapping and visualization were performed on QGIS version 2.12.2.
GeoSentinel's data collection protocol has been approved by the Boston Medical Center Institutional Review Board (IRB) and reviewed by the IRB at the National Center for Emerging and Zoonotic Infectious Diseases at the Centers for Disease Control and Prevention and classified as public health surveillance and not human subjects research.
Results

Patient Population
During the 16-year study period, 74 patients were diagnosed with probable (n ¼ 25) or confirmed (n ¼ 49) pertussis (Table 1) Table 2 ).
Trip Characteristics
Tourism was reported most frequently as the reason for travel (41; 55%), followed by business (26; 35%) ( Table 1) . Country of exposure was defined by the clinician in 59 cases and by the authors in 7 (Figure 2 ). Country of exposure could not be determined for eight individuals who had traveled to two or more countries where exposure could have occurred (i.e. during the incubation period for pertussis). The most common countries of exposure were India (n ¼ 10; 15%), China (n ¼ 10; 15%) and Thailand (n ¼ 4; 6%). Twenty-eight (39%) patients had a pretravel visit.
Clinical Presentation
Nine patients (12%) were seen during travel and 65 (88%) after travel. Median time between return from travel and GeoSentinel clinic visit was 35 days (IQR 12-64 days] for those 65 patients seen after travel. Seventy of 74 patients (95%) had respiratory symptoms, while fatigue and fever were seen in 21 (28%) and 20 (27%), respectively. Median duration of symptoms before clinic visit was 48 days (IQR, 19-69 days). Data on secondary cases were not available through GeoSentinel.
Discussion
We report 74 cases of pertussis in returning travelers, the largest case series of travelers with pertussis. Together with other reports, 10, 11 this study highlights the importance of respiratory illness and this particular pathogen in returning travelers. Given the infectiousness of pertussis, a returning traveler could be a source of additional cases in his/her home country, The geographical diversity of exposure countries suggests that providers should consider the diagnosis in returning travelers coming from temperate and tropical regions as well as developed and less-developed nations. The relatively long interval between travel and clinic visit suggests that travelers may delay seeking medical attention until their symptoms fail to improve after a few weeks. Alternatively, it could be due to a delay in diagnosis; providers must remain vigilant about this possibility for those with recent and more remote travel and compatible symptoms. This study also highlights the importance of pertussis immunization as part of the pre-travel visit. The travel clinic consultation provides an opportunity to ensure that travelers are up to date with tetanus/diphtheria/acellular pertussis (Tdap) vaccine along with all other routine vaccines. [14] [15] [16] Studies conducted in Singapore, Australia, and France showed that 3%, 12%, and 13% of travelers, respectively, received a pertussis booster during the previous ten years, suggesting a gap in vaccine administration in the adult population. [17] [18] [19] Due to the nature of GeoSentinel data collection, we did not have information on the immunization status of these individuals.
We found an increase in cases after 2005, which coincides with the increase in reported incidence of pertussis, both in the United States and worldwide. This rise has occurred despite introduction of acellular pertussis vaccine for adults and high immunization rates in children. 20, 21 Cases have also been detected in migrants and adoptees -travelers that may not always be detected by routine surveillance systems. 22, 23 Recommendations for adult booster vaccinations were made at different times in different countries and personal uptake of the booster may be variable. This rise could be due to changes in the pathogen itself, such as vaccine-induced selection of certain Bordetella pertussis strains. 2, 24 The rise in cases may also reflect waning of the immune response over time, [25] [26] [27] which is supported by the older age of travelers with pertussis in this study (90.2% were 19 years of age). Third, there is concern about lesser efficacy of the acellular vaccine, introduced in the 1990s, compared to the whole cellular vaccine. 28 Fourth, our findings could be secondary to an increase in diagnosis because of increased clinical awareness and/or improved diagnostics with the advent of PCRbased tests. 1 Lastly, the increase may reflect reporting bias, because there was an overall increase in the number of reports sent to GeoSentinel over this time frame (as a result of an increased number of GeoSentinel sites). Due to the nature of the GeoSentinel data collection form, there is no information on how the diagnosis was made, but we were able to obtain this information retrospectively from a subset of sites. In general, diagnoses were based on compatible symptoms in conjunction with serology, culture or PCR. Standardization of the clinical case definition for pertussis in the GeoSentinel Surveillance system is warranted. For example, the WHO clinical case definition for pertussis is a person with a cough lasting at least 2 weeks with at least one of the following symptoms: (i) paroxysms (i.e. fits) of coughing; (ii) inspiratory whooping; or (iii) post-tussive vomiting (i.e. vomiting immediately after coughing) without other apparent cause. 29 A clinical definition is especially important for pertussis, as laboratory methods available today have important limitations, and test characteristics vary depending on duration of symptoms. Among other factors, use of culture as a diagnostic for pertussis is limited by the skill required to obtain appropriate samples and the lower sensitivity compared to PCR. 30 Serologic testing lacks established cut-points and standardization, can cross-react with other Bordetella species, and must address the timevarying immune response. Even PCR-based methods have been associated with false-positives due to cross-contamination during specimen collection in rooms where the vaccine had been administered 31 and non-specific cross-reactions from other Bordetella species 30 ; PCR tests are more expensive and may not be available at all sites.
Our study has several other limitations. The GeoSentinel Surveillance Network captures data only for travelers who visit GeoSentinel clinics; these data do not represent all international travelers. Because of the lack of denominator data on number of persons traveling, GeoSentinel Surveillance data during the period of data collection cannot be used to calculate absolute risk. Lastly, it is possible that pertussis was acquired locally and not during travel; the determination of travel-associated pertussis was made by each clinician based on onset of symptoms and history of travel, but the precise timing of infection cannot be determined.
This GeoSentinel analysis of B. pertussis infections enabled us to describe characteristics of travelers with pertussis and the countries where they were likely exposed. We found that destinations in Asia, particularly in India and China, were frequent areas of acquisition of B. pertussis infection. Our data highlight the importance of considering routine vaccines during pre-travel Figure 2 . Country of exposure to pertussis in 66 travelers seen in clinics participating in the GeoSentinel Network. consultation by travel medicine providers and primary care providers alike. This information also raises awareness of this disease as a cause of respiratory symptoms in the returning traveler, regardless of destination.
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